About 755 participants have been vaccinated in phase 1 & 2 clinical trials. No serious adverse events have been reported to be related to the vaccine in phase 1 and 2 clinical trials, Bharat Biotech said.
The rollout of Covid-19 vaccine by Bharat Biotech for the general public may get delayed as the All India Institute of Medical Sciences (AIIMS), where its Phase-III human clinical trial is underway, is struggling to find takers of the trial shots, the official heading the project told IANS.
Bharat Biotech's Covaxin was "well-tolerated" in all dose groups, the company said Wednesday as it released interim findings of phase 1 trials.
The applications of Bharat Biotech, Serum Institute and Pfizer seeking emergency use authorisation for their COVID-19 vaccines are being examined, the Centre said on Tuesday asserting that drug regulator DCGI seeking more data from these companies will not impact the vaccine-roll out timeline.
Amid a race to get the best COVID-19 vaccine, rumour mills are also abuzz with one speculation or the other. The Ministry of Health and Family Welfare today denied a report about the rejection of Serum Institute of India and Bharat Biotech's emergency-use authorisation of their respective vaccines. It said that the report was "fake".
The visit by the heads of foreign missions arranged by the Ministry of External Affairs (MEA) is part of India's efforts to develop partnerships for the manufacture and delivery of vaccines.
India COVID Vaccine: Last month, the Foreign Ministry had briefed over 190 heads of diplomatic missions and representatives of leading international organisations on Covid-related issues.
Covaxin, the COVID vaccine candidate by Hyderabad-based vaccine manufacturer Bharat Biotech Limited, being developed in collaboration with the Indian Council of Medical Research (ICMR), is likely to be available for use of the general public by the end of February 2021, Dr Sanjay Roy, principal investigator (PI) heading its clinical trial at AIIMS, told IANS on Tuesday.
After vaccine major Serum Institute of India (SII), Bharat Biotech on Monday applied to the Drugs Controller General of India (DCGI) for emergency use authorisation for its indigenously developed coronavirus vaccine called Covaxin.
Just hours after Haryana Health minister Anil Vij, who took a trial dose of Covaxin a fortnight ago, tested positive for coronavirus on Saturday, the vaccine developer Bharat Biotech issued a statement saying, ''Covaxin is designed to be efficacious''.
The vaccine developer said that the clinical trials are based on a 2-dose schedule, given 28 days apart, and vaccine efficacy will be determined 14 days after the second dose.
Top News
Latest News
